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PromotionCritical to health promotion is surveillance of tobacco use that is a leading risk factor for cardiovascular
diseases (CVDs). The objective of this paper is to analyze information from global tobacco surveys as rel-
evant for CVD prevention and, hence, for cardiologists implying their role in clinical and policy settings
for advancing tobacco control. This article uses MPOWER strategy as a framework to discuss information
available from The Global Tobacco Surveillance System (GTSS) established in 1998. Data underline the
need for cardiologists to 1) step up their efforts in promoting and providing cessation services in clinical
settings; 2) become tobacco control advocates and support policy implementation in their countries; 3)
raise patient and community awareness of harm caused by tobacco use and SHS exposure to health; 4)
undertake policy relevant research where required; and 5) support national governments in effective
implementation of provisions of the Framework Convention on Tobacco Control (FCTC).Surveillance is the ongoing, systematic collec-
tion, analysis, and interpretation of health-related
data essential to the planning, implementation,
and evaluation of public health practice. Critical
to health promotion is the surveillance of tobacco
use that killed almost 6 million people in 2010
and is globally the second leading risk factor (9%)
for mortality [1].
Worldwide, cardiovascular diseases (CVDs) are
leading killers (31% of all-cause mortality) across
all nations and at all income levels. Cardiologists
well recognize tobacco use and exposure to second-
hand smoke (SHS) as major risk factors for CVDs.
Smoking increases the risk of coronary heart disease
and stroke by 2–4 times each and is estimated to
cause 10% of CVDs [2]. Secondhand smoke is
nearly as dangerous even on brief exposure [3]
and causes 18 times more deaths by CVDs than
by lung cancer [4]. Smokeless tobacco is not safe
either. As compared to nonusers, smokeless tobaccoProject STEPS, Public Health Foundation of India, New Delhi
and Tobacco Control, Public Health Foundation of India, Newuse increases the risk of fatal myocardial infarction
and fatal stroke by 1.13 and 1.4 times, respectively
[5].
Projections up to 2030 indicate that CVDs will
continue to be leading killers, and tobacco-attribut-
able deaths will further rise to 8.3 million with the
greatest burden seen in developing countries [6].
This underscores the need to set up a tobacco sur-
veillance system at the global level and use this stra-
tegic information to guide tobacco control efforts
and to assess their impact on related CVD morbid-
ity and mortality.
Prior to 1998, representative data on tobacco
use were available mainly from developed
countries. These not only provided insight into
the tobacco epidemic, but they also contributed to
understanding the significant impact of specific
price, nonprice, and tax policies on reducing tobac-
co use and associated morbidity and mortality [7].
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2003 showed an estimated 23,520 fewer lung can-
cer deaths [8]. Analysis of similar data in Italy con-
firmed that the ban on smoking in public places
reduced hospital admissions for acute myocardial
infarction by 11% [9].
Surveillance of tobacco use as an important
CVD risk factor is crucial for predicting the future
burden and distribution of CVDs and for guiding
potential interventions to reduce the projected bur-
den. The objective of this paper is to understand
the relevance of information available from global
tobacco surveys for CVD prevention and how car-
diologists can use this information in clinical and
policy settings for advancing tobacco control.GLOBA L TOBACCO SURV E Y S
The Global Tobacco Surveillance System (GTSS)
started in 1998 with the development of a survey
that focused on tobacco use among youth ages
13–15 years called the Global Youth Tobacco Sur-
vey (GYTS) [10]. The GTSS evolved to develop 3
other specialized global surveys including the Glo-
bal School Personnel Survey in 2000, the Global
Health Professions Student Survey (GHPSS) in
2005, and the Global Adult Tobacco Survey
(GATS) in 2007.
Another globally standardized survey was initi-
ated in 2001 by the World Health Organization
(WHO), the WHO STEPwise approach to Sur-
veillance (STEPS) of risk factors related to non-
communicable diseases. However, the STEPS
survey collects information on multiple risk factors
for noncommunicable diseases and only limited
information on tobacco use is collected. The Inter-
national Tobacco Control Policy Evaluation Pro-
ject is another global effort for tobacco
surveillance. It is the first-ever international cohort
study of tobacco use to survey tobacco use at the
individual level.
Coverage provided by global surveys. By 2008,
GYTS had been conducted in 154 WHO member
states and 13 other areas. Among these, 107 coun-
tries were surveyed twice and 10 countries were
surveyed thrice [10]. Though initiated in 2000 on
the heels of GYTS, the Global School Personnel
Survey achieved much more limited coverage
[11]. GHPSS also covered only 49 WHO member
states and 1 geographic region until 2008 [12].
GATS was added to GTSS in 2007 and was con-
ducted from 2008 to 2010 in 14 developing coun-
tries, where more than one-half of the world’spopulation and smokers live (Bangladesh, Brazil,
China, Egypt, India, Mexico, Philippines, Poland,
Russian Federation, Thailand, Turkey, Ukraine,
Uruguay, and Vietnam) [13].
The International Tobacco Control Policy
Evaluation Project surveys are limited to 20 coun-
tries that are inhabited by 50% of the world’s pop-
ulation and 70% of the world’s tobacco users [14].
There is some overlap in variables being captured
by different sets of global surveys. This paper con-
siders data from the GTSS surveys for discussing
the relevance and implications for cardiologists
because of much wider coverage attained by
them.
Information from data has been analyzed in the
MPOWER framework of 6 evidence-based tobac-
co control measures: Monitor tobacco use and pre-
vention policies; Protect people from tobacco
smoke; Offer help to quit tobacco use; Warn about
the dangers of tobacco; Enforce bans on tobacco
advertising, promotion, and sponsorship; and Raise
taxes on tobacco.MPOWER S P E C I F I C DA TA F ROM GT S S
Information on tobacco use and prevention
policies (monitoring). In 11 of 14 countries sur-
veyed by GATS, more than 1 in 4 adults use tobac-
co. Smoking prevalence among adults ranges from
14% in India to 39% in the Russian Federation.
Whereas smoking in India may appear low at
14%, tobacco use is still high at 35% due to wide-
spread use of smokeless tobacco [11]. High levels
of tobacco use imply substantially more CVD cases.
Data also indicate shifting of the tobacco epidemic
to developing countries over time [15]. CVD mor-
tality peak lags behind the peak in tobacco use by
almost 3 decades (Fig. 1) [16]. Early stages of the
tobacco epidemic in developing countries imply
continued rise in CVD mortality in those countries
for the next few decades [16].
GYTS found that among adolescents (13–
15 years), 12% of boys and nearly 7% of girls smoke
cigarettes and another 12% and 8% use other to-
bacco products, respectively [12]. Susceptibility to
initiate smoking is higher than current smoking
in all regions among both boys and girls (except
boys in the West Pacific) at 19% each [11]. Early
initiation leads to lifelong addiction and much
higher CVD mortality at younger ages [17]. Teen-
age girls are as likely to smoke cigarettes as boys are
in 58% of GYTS-surveyed countries [12]. This
could potentially lead to a much narrower sex gap
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Figure 1. A model of the cigarette epidemic. Reproduced from Tobacco Control, A. D. Lopez, N. E. Collishaw, T. Piha, volume 3, 1994,
with permission from BMJ Publishing Group Ltd [16].
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101in tobacco use among adults from this cohort in the
future. Consequently, we may witness much higher
CVD mortality in women in coming decades.
These surveillance data underscore the need to pre-
vent tobacco initiation among adolescents, espe-
cially girls, to avoid future substantial CVD
morbidity and mortality.
Of note, health professionals (doctors, dentists,
nurses, and pharmacists), who are an influential
group to advise patients and the general public to
quit, themselves smoke cigarettes (20%) or use
other tobacco products (10%) as revealed by
GHPSS [12]. To be effective cessation counselors
and tobacco control advocates, it is essential for
health professionals to quit themselves and make
their institutions tobacco-free.
Information on protection of people from tobacco
smoke (protect). Over 85% of the deaths from SHS
exposure result from CVDs [4]. SHS exposure
equivalent to as little as one-half to 1 cigarette
per day increases the risk of coronary heart disease
by 25–30% [18]. However, only 11% of people live
in countries with national comprehensive smoke-
free laws. GYTS data has revealed alarmingly high
SHS exposure rates. Globally, SHS exposure at
public places and homes was reported by 50%
and 40% of students, respectively, in the week pre-
ceding survey, with the highest being in Europe
(86% and 78%, respectively) [12]. This highlights
the clear role of cardiologists in informing theirsmoking patients to quit smoking or avoid its use
in the presence of their children.
Among GATS-surveyed countries, SHS expo-
sure rates at home and at the workplace varied
from 16.5% to 73%. Adults in China, Bangladesh,
Vietnam, and Egypt reported very high (>50%)
SHS exposure rates. Even 44–72% of health pro-
fessionals surveyed under GHPSS report SHS
exposure at home or in public places. Physicians
at the primary level and cardiologists have an
important role in sensitizing smokers to protect
their children, spouses, and coworkers from expo-
sure to SHS. This will reduce the enormous
CVD burden due to SHS exposure and will further
promote smoke-free community norms [11]. Car-
diologists also need to come forward as advocates
of smoke-free policies, promoting them at their
own healthcare establishments, as well as national
and international levels, and also ensuring that car-
diology conferences are completely smoke-free.
Information on help offered to quit tobacco use
(offer). Smoking cessation can eliminate the excess
risk of CVDs to one-third within 2 years of cessa-
tion and to nil within 10–14 years of cessation [17].
Despite substantial benefits in reducing CVD mor-
bidity and mortality, demand for cessation services
and availability of such services are very low. More
than 50% of daily users use tobacco within an hour
after waking up, as per data from GATS-surveyed
countries (except Mexico) [11]. Such a high level
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quitting.
Among student smokers, 69% want to quit. In
GATS-surveyed countries, 52% of adult smokers
in India to 16% in China desire to quit within
the next year. However, access to cessation services
is suboptimal in most developing countries, and
only 9 high- and middle-income countries, cover-
ing just 5% of the world’s population, offer com-
plete cessation services, indicating the need to
increase access to and availability of these services.
The GHPSS surveys indicate a wide gap in
training of health professionals to help patients in
quitting. Merely 19–33% of students in different
health professions report that they have received
formal training in patient counseling for quitting,
though most (>85%) believe that they have a role
and should receive such training [12].
In actual practice, only 41–77% of adults re-
ported that their healthcare provider elicited their
smoking history and only 17–67% were advised
to quit. In 8 of 14 GATS-surveyed countries, less
than 50% of adults were advised to quit [11]. This
is a missed opportunity and must be addressed
through effective integration of tobacco cessation
into the existing health system of the country. Car-
diology patients can benefit from tobacco cessation
more than preventive strategies such as blood
pressure or cholesterol control [19]. However,
knowledge, interest, and attitudes of cardiologists
regarding smoking cessation assistance highlight
poor commitment to this important preventive
practice [20]. This indicates a vast untapped poten-
tial within the health system for generating de-
mand for tobacco cessation and for significant
reduction in CVD mortality.
Information on warnings about the dangers of
tobacco (warn). There are significant gaps in aware-
ness of CVD risks of tobacco use. In all GATS-
surveyed countries, awareness of CVD risks of
SHS is much less (1.5 times to almost 10 times)
than lung cancer risk, even though SHS-attribut-
able CVDs kill 18 times more people than SHS-
attributable lung cancer does [11]. In China and
India, where more than 40% of the world’s smokers
live, 62.4% and 38.1% of smokers, respectively, are
unaware of the CVD risk associated with SHS
exposure [11]. Awareness of the CVD risk from
SHS exposure among nonsmokers is further dis-
mally low in many countries, as little as 11.8% in
Vietnam [11].
Pictorial health warnings depicting CVD risk
can raise awareness, which is currently lacking.However, only 42 countries have mandated picto-
rial health warnings on cigarette packages, and only
19 countries (5 high-income and 14 middle-in-
come) implement ‘‘best-practice warning labels.’’
Smokeless tobacco products are further less likely
to have warnings [21]. Also, it must be noted that
even in these limited number of countries, only a
fraction of warnings are for CVDs. Further, picto-
rial health warnings nowhere have been used to
warn of CVD risk of SHS exposure [22].
Advocacy for placing CVD warnings on tobac-
co-product packages with policymakers and inclu-
sion of CVD warnings from SHS exposure is an
important area for contribution from cardiologists.
Given that messages from physicians and cardiolo-
gists have greater impact than from general public
and paramedic staff [23], cardiologists can poten-
tially contribute enormously in raising awareness
on CVD risks of tobacco use and SHS exposure
through appearance in mass-media campaigns.
Cardiology events and World Heart Day can also
be used to raise public awareness on CVD risks
of tobacco use and SHS exposure.
Information on bans on tobacco advertising,
promotion, and sponsorship (enforce). A total
ban on advertising, promotion, and sponsorships
is needed to prevent tobacco companies from moti-
vating people to initiate and continue tobacco use
[24]. However, only 19 countries with 6% of the
world’s population enforce such bans. More than
100 countries enforce partial bans, whereas 71
countries either have no ban at all or do not ban to-
bacco advertising on national TV, radio, and print
media [21].
In the GATS surveys, up to 54% of adults re-
ported having seen cigarette advertisements on
any channel, up to 21% reported coming across a
cigarette promotion activity and up to 7% reported
seeing a tobacco company associated with a sports
event [11]. Analysis of the 2000–2007 GYTS data
revealed that overall, 14.9% of students owned an
object with a cigarette brand logo on it and 10%
had been offered free cigarettes by a tobacco com-
pany representative [25]. These indicators high-
light the vulnerability of adolescents to tobacco
advertisements and promotions. In addition, these
data underscore the need for cardiologists to en-
gage with policymakers and to advocate for com-
plete prohibition of advertising, promotion, and
sponsorship by the tobacco industry.
Information on taxes on tobacco (raise). Increasing
tobacco prices through raising taxes is the most
effective intervention to reduce tobacco use and
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103encourage smokers to quit [24]. Whereas taxes
constitute more than one-half of the retail price
of a cigarette in 76% of high-income countries, it
is so only in 45% of middle-income, and 27.5%
of low-income countries [21]. It is ironic that
countries on the lower side of income level, which
can benefit most from raising taxes on tobacco (in
terms of both higher revenues and reduction in dis-
proportional burden of CVDs) have lower taxes.
Cardiologists usually serve on various government
policy committees and in that capacity can advise
their local governments to raise taxes across all to-
bacco products at state and federal levels. This will
make tobacco products more expensive and unaf-
fordable for the poor and youth in those countries,
thereby facilitating significant reductions in usage.RO L E P LAY ED BY CARD I O LOG I S T S I N
TOBACCO CONTRO L
In most countries where declines in population to-
bacco use have been achieved, healthcare profes-
sionals, particularly physicians, have played a key
role and have been at the forefront of tobacco con-
trol efforts [26]. Recognizing the critical role and
potential of healthcare professionals in driving
reductions in population tobacco use, WHO
adopted a code of practice on tobacco control that
exhorts healthcare professionals to lead by example
by reducing smoking among themselves, acting as
role models for their patients, and introducing to-
bacco control in the public health agenda of their
country [27]. The World Heart Federation, a pre-
mier professional organization in cardiology, has
endorsed this code for implementation [28].
Taking this into consideration, cardiologists and
their associations are taking the lead in tobacco
control and adding a voice to the movement. To-
bacco control has remained a key topic at the
World Congress of Cardiology successively in
2010 and 2012. Both congresses featured a rich
content in tobacco control with top global and re-
gional tobacco control leaders [29].
Uruguay in South America effectively used the
Framework Convention on Tobacco Control road-
map to register one of the steepest declines in
smoking. Philip Morris was threatening its efforts
with a lawsuit in 2010 for alleged violations of a
bilateral trade treaty. However, the CardioSur2010
congress organized by the South American Cardi-
ology Society mobilized regional cardiology socie-
ties to stand behind strong tobacco control.Cardiology societies from 10 countries also signed
the declaration for a ‘‘South America Free of To-
bacco Smoke’’ [30]. Another good example is from
Colombia where the Colombian Society of Cardi-
ology worked closely with policymakers and testi-
fied before legislative commissions to enact a
strong, comprehensive law on tobacco control in
July 2009. Local efforts in Colombia were also
strengthened with regional support from the Inter-
American Heart Foundation, a long-time leader in
tobacco control [31]. The Global Smokefree Part-
nership recognized its contribution through the
2009 Award for Leadership and Excellence in
Smoke-Free Policy.
Evidence from tobacco surveillance data indi-
cates the need for action at the level of patients,
community, and policymakers. The unique status
of cardiologists as clinicians, health role models,
and opinion leaders can be leveraged at all these lev-
els to advance tobacco control and prevent CVDs.
Given that tobacco cessation has nearly as great a
benefit as that accrued from other treatments such
as cholesterol-lowering or blood pressure-lowering
medicines to improve heart health, it is imperative
that tobacco use is assessed and documented rou-
tinely, and cessation services prioritized and consid-
ered as an effective therapeutic strategy.
GTSS data have shown a shift of the tobacco
epidemic to developing countries, which also hap-
pen to disproportionately bear the burden of
CVDs. Mainly stage 2 of the tobacco epidemic in
developing countries further implies that CVD
mortality in these countries will continue to rise
for at least 3 decades [16]. Active engagement of
cardiologists in using GTSS surveillance data to
promote MPOWER strategies at each country le-
vel will help in effective tobacco control, thus aid-
ing in plateauing the rising peak. The earlier we
achieve plateau in the rising curve of tobacco use
in developing countries through effective tobacco
control measures, the greater the reduction in
CVD mortality will be, saving numerous lives.
The role of cardiologists thus goes beyond tobacco
cessation interventions delivered to individual pa-
tients to influential advocates with the policymak-
ers and communities for comprehensive tobacco
control.
Eliciting tobacco use information in patients’
history and offering cessation services to those
who use tobacco can create greater demand for ces-
sation services and can save lives [23]. This also of-
fers an added benefit in promoting antitobacco
messages in the community and aids in positively
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ity, it is important that cardiologists themselves ab-
stain from tobacco use and make their premises and
establishments tobacco-free. GHPSS has provided
important pointers on health professionals’ atti-
tudes, practice behaviors, and patient-centered out-
comes and has highlighted the need to provide
specific training in tobacco cessation and tobacco
control as primary care physicians can play a pivotal
role in the early detection and management of to-
bacco as a CVD risk factor.
Given the advantageous status enjoyed by cardi-
ologists in society and their access to and member-
ship of governmental health policymaking bodies,
they can use these strategic opportunities to initiate
evidence-informed advocacy for comprehensive to-
bacco control with both the policymakers and the
community. Global surveys indicate major gaps in
smoke-free policies; complete bans on all direct
and indirect advertising, promotion, and sponsor-
ship; awareness of CVD risk of tobacco use and
SHS exposure; health warnings on tobacco pack-ages; and taxes on tobacco products in different
countries. The cardiologist community can strongly
highlight the tobacco-attributable CVD mortality
to policymakers and can advocate to fill the
gaps in instituting and implementing best-practice
tobacco control measures. Further, they can also
strengthen other tobacco control groups by
extending the support of their organizations to
them.
Cardiologists and all other healthcare profession-
als as well as their professional associations have crit-
ical roles to play in advancing tobacco control. There
are multiple areas of engagement where their contri-
butions can help achieve effective tobacco control,
facilitate in driving reductions in population tobacco
use, and subsequently improve CVD prevention and
control. It is encouraging that cardiologists have in-
deed assumed significant roles in tobacco control in
different countries as discussed in this paper. How-
ever, the information from global tobacco surveys
calls for a broader and more intense action from
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